Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey.

Hwang, Bella; Shroufi, Amir; Gils, Tinne; Steele, Sarah Jane; Grimsrud, Anna; Boulle, Andrew; Yawa, Anele; Stevenson, Sasha; Jankelowitz, Lauren; Versteeg-Mojanaga, Marije; +5 more... Govender, Indira; Stephens, John; Hill, Julia; Duncan, Kristal; van Cutsem, Gilles; (2019) Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey. PloS one, 14 (3). e0212405-. ISSN 1932-6203 DOI: https://doi.org/10.1371/journal.pone.0212405

Abstract

BACKGROUND: HIV and TB programs have rapidly scaled-up over the past decade in Sub-Saharan Africa and uninterrupted supplies of those medicines are critical to their success. However, estimates of stock-outs are largely unknown. This survey aimed to estimate the extent of stock-outs of antiretroviral and TB medicines in public health facilities across South Africa, which has the world's largest antiretroviral treatment (ART) program and a rising multidrug-resistant TB epidemic. METHODS: We conducted a cross-sectional telephonic survey (October-December 2015) of public health facilities. Facilities were asked about the prevalence of stock-outs on the day of the survey and in the preceding three months, their duration and impact. RESULTS: Nationwide, of 3547 eligible health facilities, 79% (2804) could be reached telephonically. 88% (2463) participated and 4% (93) were excluded as they did not provide ART or TB treatment. Of the 2370 included facilities, 20% (485) reported a stock-out of at least 1 ARV and/or TB-related medicine on the day of contact and 36% (864) during the three months prior to contact, ranging from 74% (163/220) of health facilities in Mpumalanga to 12% (32/261) in the Western Cape province. These 864 facilities reported 1475 individual stock-outs, with one to fourteen different medicines out of stock per facility. Information on impact was provided in 98% (1449/1475) of stock-outs: 25% (366) resulted in a high impact outcome, where patients left the facility without medicine or were provided with an incomplete regimen. Of the 757 stock-outs that were resolved 70% (527) lasted longer than one month. INTERPRETATION: There was a high prevalence of stock-outs nationwide. Large interprovincial differences in stock-out occurrence, duration, and impact suggest differences in provincial ability to prevent, mitigate and cope within the same framework. End-user monitoring of the supply chain by patients and civil society has the potential to increase transparency and complement public sector monitoring systems.